Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of prophylactic versus intermediate doses of enoxaparin in hospitalized COVID-19
2020-001891-14Phase 2Active
- Sponsor
- Fundación Neumosur
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of enoxaparin in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Fundación Neumosur. Primary endpoint: Composite of oxygen therapy escalation, invasive mechanical ventilation, or mortality during admission. Started May 2020; status: active.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on 2020-001891-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001891-14.